B4GALT3 and sarcoma: High expression of B4GALT3 was associated with poor prognosis of overall survival in adenoid cystic carcinoma (ACC) (p = 0.003), CESC (p = 0.014), liver hepatocellular carcinoma (LIHC) (p = 0.0059), MESO (mesothelioma) (p = 0.02), sarcoma (SARC) (p = 0.044), and HNSC (p = 0.04) cancers based on the GEPIA2 web tool analysis (Supplementary Figures 1B–G).